Getting your player ready...
MUNICH, Germany — Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of the New England Journal of Medicine urged Tuesday.
The journal published results online from one study and an analysis of partial results from two others. They also were presented at a cardiology conference in Munich.
In July, preliminary results from a study on whether Vytorin could prevent damage to the heart’s aortic valve from worsening raised concerns. Doctors saw more cancer cases in those taking it compared with others given placebos.
